ReViral
Edit

ReViral

https://www.reviral.co.uk/?refid=73
Last activity: 07.04.2022
Categories: MarketDevelopmentCommerceBioTechMovingMedTech
ReViral – Innovative therapies for viral diseases ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds. The first target is Respiratory Syncytial Virus (RSV) treatment which represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity. As its first program, ReViral is developing a novel, highly potent, small molecule inhibitor of RSV fusion RV521 which has completed its Phase 1 clinical studies and has shown significant activity in phase 2 clinical studies in adult volunteers. RV521 is now moving towards phase 2 studies in infant and adult patients.
Followers
1.13K
Mentions
16
Location: United Kingdom, England, Stevenage
Employees: 11-50
Total raised: $99M
Founded date: 2011

Investors 5

Funding Rounds 2

DateSeriesAmountInvestors
01.09.2020Series C$44M-
01.08.2018Series B$55MNew Leaf V...

Mentions in press and media 16

DateTitleDescriptionSource
07.04.2022A-Rod-backed sports betting app Mojo wants to let you bet on...This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ...fortune.co...
01.09.2020SBC company ReViral raises $44 million in Series C financingLondon & Research Triangle Park, N.C. - ReViral Ltd., a clinical-stage biopharmaceutical company...cambridgen...
01.09.2020SBC company ReViral raises $44 million in Series C financingSBC company ReViral raises $44 million in Series C financing 01-09-2020 London & Research Tria...cambridgen...
28.08.2020Reviral raises $44 million in Series C financing ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and c...anderapart...
27.08.2020UK biopharma startup ReViral lands $44M Series CCR-CP Life Science Fund, the joint VC vehicle of Charoen Pokphand Group and China Resources Capital ...pitchbook....
25.08.2020ReViral Raises $44 Million in Series C Financing-orbimed.co...
10.12.2018Cambridge companies feature in SyndicateRoom's Top 100Cambridge companies feature in SyndicateRoom's Top 100 10-12-2018 What are the hottest companies o...cambridgen...
02.08.2018Term Sheet — Thursday, August 25 Qs WITH A DEALMAKER Good morning, Term Sheet readers. Paid Content Securing the enterprise witho...fortune.co...
01.08.2018ReViral closes $55 million Series B funding round for RSV dr...The company plans to use the funding to move its lead drug candidate, RV521, into Phase IIa studies ...medcitynew...
01.08.2018Re­Vi­ral gets a $55M boost­er shot of cash as it ex­pands i...Six months af­ter Re­Vi­ral out­lined the ef­fi­ca­cy of their res­pi­ra­to­ry syn­cy­tial virus, or...endpts.com...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In